Andes Biotechnologies is a privately held biotechnology company. The company’s lead investors include Aurus Bios, a fully owned subsidiary of Aurus S.A., and Austral Capital Partners.

Andes Biotechnologies is a leading nucleic acid-based drug discovery and Development Company focused on solid tumor cancers. The company has discovered two novel families of long noncoding RNAs: sense (S-RNA) and antisense noncoding (AS-RNA). Both are present in all human cells, are synthesized in the mitochondria and migrate to the nucleus.  The proprietary technology developed by Andes Biotechnologies is based on oligonucleotide therapeutics that target the novel long noncoding regulatory RNA that is present in a variety of cancer indications.

Aurus Bios is the first Chilean Venture Capital Fund to invest exclusively in Life Sciences companies in the biotechnology, pharmaceuticals, diagnostics, medical devices, nutraceuticals, wellness, agbio and industrial biotech sectors, among others.  The Fund is both focused on financing the different stages of intellectual property development as well as providing growth capital for emerging companies.  The fund’s team brings together years of experience in Life Sciences, and is fully committed to delivering solid results to its investors and portfolio companies.

Austral Capital is a venture capital firm focused on identifying globally scalable, high growth entrepreneurs and technologies.  Austral Capital catalyzes the success of its portfolio companies by active board participation, funding support and access to influential networks.  Austral Capital backs only the best entrepreneurs, those with a clear vision, commitment, ethics and an outstanding ability to execute.


Releases & Media Coverage